The Food and Drug Administration issued a warning that a class of type 2 diabetes drugs in rare cases might cause flesh-eating bacterial infection of genitals.

A failed drug tested on people with osteoarthritis pain might prevent opioid tolerance and physical dependence when used with opioid-based pain medications.

Indiana received federal approval to require some low-income residents to work, study or perform public service to qualify for Medicaid.

Alex Azar, criticized by women's rights groups for comments that life begins at conception, was sworn in Monday as chief of Health and Human Services.

As experimental drugs fail to stop Alzheimer's from destroying memory, experts now wonder if research into the brain disease has gone in the wrong direction.

The U.S. Senate confirmed former pharmaceutical executive Alex Azar as the new head of the Department of Health and Human Services on Wednesday.

Teva Pharmaceutical Industries plans to cut more than one-quarter of its workforce -- 14,000 positions worldwide -- over two years as part of restructuring.

President Donald Trump on Monday nominated former pharmaceutical executive Alex Azar to lead the U.S. Department of Health and Human Services.

Hundreds of people in Indiana's capital city came together to set a world record by painting a massive chalk pavement mural.

Eli Lilly announced Thursday it is cutting 8 percent of its workforce -- 3,500 jobs -- in an effort to streamline operations and focus on developing new drugs.

A host of new drugs that appear to prevent migraine headaches are in the final stages of testing and approval in the United States, researchers report.

President Donald Trump told leading drugmakers at the White House to cut "astronomical" drug prices and offered to help them with quicker approval of medicine.

Escalating prices of the drug naloxone may threaten efforts to reduce opioid-related deaths across America, a team at Yale University and the Mayo Clinic warns.

Insulin, a life-saving medication used to treat diabetes, was discovered nearly 100 years ago, yet the drug's price has spiked 700 percent in just two decades.

Solanezumab, a promising experimental drug to treat Alzheimer's disease, failed in large trials, the Eli Lilly pharmaceutical company said.